Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Nanowires

Nanowires engineer naive T cells for immunotherapy

Nanowires enable efficient genetic engineering of non-activated naive T cells, providing a technological platform for the generation of gene-modified T cells with maximal therapeutic efficacy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Boosting T cell therapy by nanowire-based genetic engineering of naive T cells.

References

  1. Finck, A. V. et al. Nat. Med. 28, 678–689 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Gattinoni, L. et al. Nat. Rev. Cancer 12, 671–684 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gattinoni, L. et al. J. Clin. Investig. 115, 1616–1626 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yee Mon, K. J. et al. Nat Nanotechnol. https://doi.org/10.1038/s41565-024-01649-7 (2024).

    Article  PubMed  Google Scholar 

  6. Ella, S. et al. EBioMedicine 67, 2352–3964 (2021).

    Google Scholar 

  7. Ghassemi, S. et al. Nat. Biomed. Eng. 6, 118–128 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mo, F. et al. Nature 597, 544–548 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sabatino, M. et al. Blood 128, 519–528 (2016).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Themeli, M. et al. Nat. Biotechnol. 31, 928–933 (2013).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Luca Gattinoni.

Ethics declarations

Competing interests

L.G. has consulting agreements with Lyell Immunopharma, is on the scientific advisory boards of Poseida Therapeutics and Kiromic, and is a stockholder of Poseida Therapeutics. D.S.-L. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Slavkovic-Lukic, D., Gattinoni, L. Nanowires engineer naive T cells for immunotherapy. Nat. Nanotechnol. (2024). https://doi.org/10.1038/s41565-024-01651-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41565-024-01651-z

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research